Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT02951156 |
| Title | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Pfizer |
| Indications | |
| Therapies |
Avelumab + Azacitidine + Utomilumab Avelumab + Rituximab + Utomilumab |
| Age Groups: | senior | adult |
| Covered Countries | USA | ITA | ESP | BEL |